Back to search

Article

A Novel dual Influenza virus and SARS-CoV-2 neutralisation assay

2025-09-23

Abstract excerpt

Influenza and SARS-CoV-2 are co-circulating during the traditional influenza season giving rise to potential co-infections; currently estimated at 2.4%. Additionally, this means that the uptake of both vaccines (including SARS-CoV-2 boosters) will be encouraged within the same timeframe. Currently, patients receive separate vaccines in different arms on the same or different days. Induction of neutralising antibod...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8d0c4122-211e-5b2b-a475-91be781d9e21
DOI
10.1101/2025.09.19.677384
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Novel dual Influenza virus and SARS-CoV-2 neutralisation assayDOI 10.1101/2025.09.19.677384
Optimisation of a multiplexed, high throughput assay to measure neutralising antibodies against SARS-CoV-2 variantsSemantic proximity
Development of a Novel Medium Throughput Flow-Cytometry Based Micro-Neutralisation Test for SARS-CoV-2 with Applications in Clinical Vaccine Trials and Antibody ScreeningSemantic proximity
A Safe Pseudotyped Lentivirus-Based Assay to Titer SARS-CoV-2 Neutralizing AntibodiesSemantic proximity
Evaluation of a novel fully automated and ELISA- based assays for detecting anti- SARS- CoV-2 neutralizing antibodiesSemantic proximity
Homogeneous Surrogate Virus Neutralization Assay to Rapidly Assess Neutralization Activity of Anti-SARS-CoV-2 AntibodiesSemantic proximity
Surrogate virus neutralisation test based on nanoluciferase-tagged antigens to quantify inhibitory antibodies against SARS-CoV-2 and characterise Omicron-specific reactivitySemantic proximity
A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodiesSemantic proximity
Development and optimisation of Influenza C and Influenza D pseudotyped virusesSemantic proximity
The study of antibody responses to influenza neuraminidase using a lentiviral pseudotype based ELLASemantic proximity
Biologically contained Ebola virus enables standardised neutralisation testing for preclinical and clinical immunogenicity assessmentSemantic proximity
Pseudotyped virus-based platform and structural analysis reveal potential cross-reactivity sites between influenza C and D virusesSemantic proximity
Developing a pseudo-lentivirus-based neutralization assay against SARS-CoV-2Semantic proximity
Select a neighboring publication to make it the new centre.